Clinical Trials Logo

Transfusional Iron Overload clinical trials

View clinical trials related to Transfusional Iron Overload.

Filter by:

NCT ID: NCT00560820 Completed - Clinical trials for Transfusional Iron Overload

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

Start date: September 2007
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the effect of deferasirox on renal hemodynamics by determining glomerular filtration rate (GFR), renal plasma flow (RPF) and filtration fraction (FF).

NCT ID: NCT00390858 Completed - Clinical trials for Transfusional Iron Overload

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Start date: September 2003
Phase: Phase 2
Study type: Interventional

In this 4-year extension study the safety, efficacy and and pharmacokinetics of deferasirox in regularly transfused pediatric patients with β-thalassemia major was assessed. Patients who successfully completed the main 1 year trial (NCT00390858) were eligible to continue in this extension trial and receive chelation therapy with deferasirox for up to 4 years.

NCT ID: NCT00379483 Completed - Clinical trials for Transfusional Iron Overload

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

Start date: July 2002
Phase: Phase 2
Study type: Interventional

A 1-year randomized Phase IIa core trial followed by a prolongation of 5 to 9 months was conducted to investigate the efficacy and safety of deferasirox in patients aged ≥ 18 years with transfusion-dependent iron overload. The objective of this extension study is to assess the long-term safety of deferasirox and to provide treatment in patients with transfusional iron overload.